01/08/2026 | Carol Alencar | Sechat

https://sechat.com.br/noticia/pesquisa-internacional-cobra-mais-rigor-cientifico-no-uso-da-cannabis-medicinal 

A scientific review highlights the lack of robust evidence on medical cannabis and reinforces the need for more rigorous and balanced research in the field

The growth in the use of medical cannabis for different clinical conditions has not been accompanied, in the same proportion, by robust scientific evidence. A study published in the Journal of the American Medical Association (JAMA) reinforces that there is consistent evidence for only a limited number of indications, while most uses continue to be supported by limited or inconclusive data. 

According to the review, which analyzed thousands of studies published over the last decade, the quality of available evidence is still considered insufficient to support broad clinical recommendations, especially in cases such as chronic pain, anxiety, and insomnia.

Despite the research findings, evidence from many clinical cases shows that cannabis has achieved satisfactory results. In an interview for Sechat's “Vidas Transformadas” (Transformed Lives) program, Daiany Dias reported a good response to the use of medical cannabis, highlighting its positive impact on coping with the effects of chemotherapy and on the quality of rest.

Where science points to clear benefits
According to the study, prescribed cannabinoid medications showed more consistent results in controlling chemotherapy-induced nausea and vomiting, stimulating appetite in patients with HIV/AIDS, and treating rare pediatric epilepsies, such as Dravet and Lennox-Gastaut syndromes. Outside of these contexts, the benefits observed were classified as modest or inconsistent when compared to established therapies.

Medical guidance, risks, and realistic expectations

For rheumatologist and clinician Dr. Tiago Campanholi, the data reinforce the need for transparency in the doctor-patient relationship. 

According to him, prescribers should recognize the fragility of current scientific evidence and inform patients that about 30% of them may experience adverse effects, including cognitive changes, psychiatric and cardiovascular effects, and risk of dependence.

"The use of medical cannabis should be treated as an adjunctive therapeutic resource, not as a miracle solution. It is essential to avoid promises, clarify that results vary, and that the goal is to improve signs and symptoms, without completely replacing conventional treatments," he explains.

The specialist also highlights the importance of detailed clinical evaluation, continuous follow-up, and frequent monitoring, with dose adjustments and analysis of possible drug interactions. In addition, he advocates the integration of cannabis with other therapeutic approaches, such as physical therapy, psychotherapy, and traditional pharmacotherapy.

“All clinical decisions must be individualized, documented, and aligned with CFM and Anvisa standards, ensuring safety, ethics, and clear information for the patient,” he concludes.